2023
Biomarkers and biosensors for early cancer diagnosis, monitoring and prognosis
Wahab M, Palaniyandi T, Ravi M, viswanathan S, Baskar G, Surendran H, Gangadharan S, Rajendran B. Biomarkers and biosensors for early cancer diagnosis, monitoring and prognosis. Pathology - Research And Practice 2023, 250: 154812. PMID: 37741139, DOI: 10.1016/j.prp.2023.154812.Peer-Reviewed Original ResearchEarly cancer diagnosisBiosensorEarly cancer detectionCancer biomarkersChip modelSuch biomarkersEngineering technologyBiological samplesCancer typesRecent advancementsEarly detectionNucleic acidsEarly diagnostic markerCancer detectionDevelopment of technologyGlobal socioeconomic impactTumor cell DNAProstate cancerMajor challengeBiomedical engineering technologyTherapeutic outcomesDetectionDiagnostic markerTechnologyParticular cancer types
2021
Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics
Ding R, Chen P, Rajendran B, Lyu X, Wang H, Bao J, Zeng J, Hao W, Sun H, Wong A, Valecha M, Yang E, Su S, Choi T, Liu S, Chan K, Yang L, Wu J, Miao K, Chen Q, Shim J, Xu X, Deng C. Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. Nature Communications 2021, 12: 3046. PMID: 34031426, PMCID: PMC8144567, DOI: 10.1038/s41467-021-23379-3.Peer-Reviewed Original ResearchConceptsSarcomatoid carcinomaEpithelial-mesenchymal transitionNasopharyngeal carcinomaCarcinoma subtypesNeck cancer typesPatient-derived organoidCRT regimensDistinct molecular featuresMalignant headHigh morbidityTreatment regimensTherapeutic responseEC subtypesPathogenic mechanismsDrug responsivenessEGFR inhibitorsNPC subtypesCancer typesSubtypesCarcinomaPrecision oncologyDrug testsMolecular landscapeRegimensMicrotubule inhibitors